Mindfulness Meditation Versus Clinical Hypnosis for Acute, Experimental Pain

Sponsor
The University of Queensland (Other)
Overall Status
Recruiting
CT.gov ID
NCT04786405
Collaborator
(none)
200
1
2
21
9.5

Study Details

Study Description

Brief Summary

This trial aims to determine the effects and mechanisms (mediators and moderators) of brief training in mindfulness meditation versus clinical hypnosis on acute, experimental pain.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness meditation
  • Behavioral: Clinical hypnosis
Phase 2

Detailed Description

Participants (N=200 with complete data) will be healthy undergraduate students or community-based individuals. An experimental, randomised trial will be implemented, with participants randomly assigned to either five daily, 20-minute mindfulness meditation sessions or clinical hypnosis sessions. Repeated measures and experimental pain manipulation will be implemented. Aim 1 is to examine the effects of these two treatments on experimental pain outcomes. Aim 2 is to examine the moderators of these effects. Aim 3 is to determine the mediators underlying improved experimental pain outcomes. Results will refine theory and will inform the future streamlining of treatments to target those mechanisms shown to be of most critical importance.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Single-blind, two-arm, parallel-group randomized design.Single-blind, two-arm, parallel-group randomized design.
Masking:
Single (Outcomes Assessor)
Masking Description:
The experimenter will remain blind to participant condition.
Primary Purpose:
Treatment
Official Title:
An Experimental, Randomized Trial Comparing Mindfulness Meditation Versus Clinical Hypnosis for Acute Pain: a Test of Effects and Mechanisms
Actual Study Start Date :
Mar 15, 2021
Anticipated Primary Completion Date :
Dec 15, 2022
Anticipated Study Completion Date :
Dec 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness Meditation

Participants in this arm will complete five, 20-minute mindfulness meditation sessions delivered over consecutive days.

Behavioral: Mindfulness meditation
Participants in the mindfulness meditation condition will practice a breath and body focused meditation.

Active Comparator: Clinical Hypnosis

Participants in this arm will complete five, 20-minute clinical hypnosis sessions delivered over consecutive days.

Behavioral: Clinical hypnosis
Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.

Outcome Measures

Primary Outcome Measures

  1. Pain unpleasantness [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    Numerical rating scale in response to exposure to a cold pressor task.

  2. Pain intensity [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    Numerical rating scale in response to exposure to a cold pressor task.

  3. Pain tolerance [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    How long (in seconds) participants tolerate the cold pressor task with the time starting at the point of immersion and stopping when the hand, wrist and forearm were withdrawn from the refrigerated water.

Secondary Outcome Measures

  1. Physiological response to pain stimulus [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    Heart rate data

  2. Mechanism: Attention Network Task [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    A computer based task that has been developed to allow assessment of the functioning of the three major attentional networks; alerting, orienting, and executive attention.

  3. Mechanism: Mind Wandering Task [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    A computer based task that has been developed to allow assessment of three types of mind wandering.

  4. Mechanism: Mindfulness [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    Five Facet Mindfulness Questionnaire-Short Form

  5. Mechanism: Pain catastrophizing [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    Pain Catastrophizing Scale

  6. Mechanism: Pain appraisals [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    Pain Appraisal Inventory

  7. Mechanism: Pain-Related Cognitive Processes [Change from Experimental Session 1 (Day 1) to Experimental Session 5 (Day 5)]

    Pain-Related Cognitive Process Questionnaire34

  8. Mechanism: Hypnotizability [Baseline score at Experimental Session 1 (Day 1)]

    Stanford Clinical Hypnotizability Scale

  9. Mechanism: Pre-treatment expectancies [Baseline score at Experimental Session 1 (Day 1)]

    Treatment Expectations Questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years of age or older;

  • Able to read, speak and understand English.

Exclusion Criteria:
  • Pregnancy, heart or vascular disease, Raynaud's disease, sickle cell disease, seizure disorder, high blood pressure, or diabetes;

  • Experience of recurrent fainting spells;

  • Report of a chronic pain condition;

  • Use of alcohol and/or pain medication in the last 24-hours;

  • Currently receiving psychiatric care;

  • Problems with allergic skin reactions or excessive bruising;

  • Previous participation in a cold pressor experiment.

  • All participants will be asked to consume a fruit box drink prior to the cold pressor to prevent vasovagal reactions.

These exclusion criteria are standard when using a cold pressor task in a healthy undergraduate population and ensure safe procedures to mitigate any potential risks.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The University of Queensland Brisbane Queensland Australia 4072

Sponsors and Collaborators

  • The University of Queensland

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The University of Queensland
ClinicalTrials.gov Identifier:
NCT04786405
Other Study ID Numbers:
  • #2019000347
First Posted:
Mar 8, 2021
Last Update Posted:
May 25, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The University of Queensland
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 25, 2022